Bivin & Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Bivin & Associates’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-600	Closed	-$1K	–	391
2021 Q4	$1K	Buy	+600	New	+$1.4K	﹤0.01%	331

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bivin & Associates's LCTX Position: Q1 2022 in Review

Bivin & Associates sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 600 shares — an estimated $1K sold.

Bivin & Associates first reported a position in LCTX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

Bivin & Associates reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
Bivin & Associates sold 600 Lineage Cell Therapeutics shares in Q1 2022, an estimated $1K.
Bivin & Associates first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 1 quarter.
Bivin & Associates's Lineage Cell Therapeutics position peaked at $1K in Q4 2021.
110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.